比例辅助通气用于缩短机械通气持续时间
该国际临床试验纳入已机械通气至少24小时、能接受PSV部分通气支持但尚未准备脱机的成人患者,随机接受PAV+(目标为正常呼吸功)或PSV(目标为正常呼吸频率和潮气量)。共23个中心、7个国家、722例入组,573例随机并纳入分析。PAV+组成功脱离机械通气的中位时间为7.3天(95%CI 6.2–9.7),PSV组为6.8天(95%CI 5.4–8.8),P=0.58。无呼吸机天数、再插管率、气管切开率及第90天死亡率(PAV+组29.6% vs PSV组26.6%)等次要结局两组相似。
要点
- PAV+组成功脱离机械通气中位时间7.3天(95%CI 6.2–9.7)vs PSV组6.8天(95%CI 5.4–8.8),差异无统计学显著(P=0.58)。
- 第90天死亡率PAV+组29.6% vs PSV组26.6%,两组相似。
- 无呼吸机天数、再插管率和气管切开率两组相似。
- 第28天咪达唑仑等效剂量相对基线的平均差:PAV+组-1.51±3.28 mg/kg vs PSV组0.04±0.97 mg/kg。
- 严重不良事件PAV+组31例(10.8%)vs PSV组28例(9.8%),P=0.79。
适用人群与场景
- 成人患者,已接受机械通气至少24小时,能接受PSV部分通气支持但尚未准备脱离机械通气。
处置流程与药物剂量
- PAV+组采用比例辅助通气联合可调负荷增益因子,目标为正常呼吸功。
- PSV组采用压力支持通气,目标为正常呼吸频率和潮气量。
研究设计与关键结果
- 国际临床试验,23个中心、7个国家,722例入组,573例随机并纳入分析;主要终点为从随机化到成功脱离机械通气的时间。
- PAV+组成功脱离机械通气中位时间7.3天(95%CI 6.2–9.7)vs PSV组6.8天(95%CI 5.4–8.8),P=0.58。
- 第90天死亡率PAV+组29.6% vs PSV组26.6%,两组相似;无呼吸机天数、再插管率和气管切开率两组相似。
- 第28天咪达唑仑等效剂量相对基线的平均差:PAV+组-1.51±3.28 mg/kg vs PSV组0.04±0.97 mg/kg。
- 严重不良事件PAV+组31例(10.8%)vs PSV组28例(9.8%),P=0.79。
证据类型、等级与局限
- 证据类型:国际随机对照临床试验(PROMIZING,NCT02447692)。
- 由加拿大卫生研究院等资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在能接受部分通气支持但尚未准备脱机的成人患者中,PAV+与PSV在成功脱离机械通气时间上无显著差异,不支持以缩短脱机时间为目的常规替换PSV为PAV+。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear.
METHODS: In this international clinical trial, we randomly assigned adult patients who had been receiving mechanical ventilation for at least 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (which targeted a normal respiratory rate and tidal volume). The primary outcome was the time from randomization to successful liberation from mechanical ventilation.
RESULTS: Across 23 centers in seven countries, 722 patients were enrolled, and 573 underwent randomization and were included in the analysis. The median time to successful liberation from mechanical ventilation was 7.3 days (95% confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV group (P = 0.58). The median number of ventilator-free days, the incidence of reintubation and tracheostomy, and the incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which were secondary outcomes, were similar in the two groups. With respect to sedative drugs, the mean (±SD) difference in the midazolam-equivalent dose at day 28 relative to the baseline dose was -1.51±3.28 mg per kilogram of body weight in the PAV+ group and 0.04±0.97 mg per kilogram in the PSV group. Serious adverse events occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P = 0.79).
CONCLUSIONS: The time to liberation from mechanical ventilation did not differ significantly between the group that underwent PAV+ and the group that underwent PSV. (Funded by the Canadian Institutes of Health Research and others; PROMIZING ClinicalTrials.gov number, NCT02447692.).
参考来源
- Bosma KJ, Burns KEA, Martin CM, et al. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. N Engl J Med. 2025. PMID: 40513024. doi:10.1056/NEJMoa2505708
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。